DjelicS/E+ via Getty Images Progyny's (NASDAQ:PGNY) Q2 results were less than stellar, as the stock sold off significantly after lowering their full-year revenue guidance. Currently, Progyny is down over 40% YTD and down nearly 30% since my last article. I believe the company's long-tern thesis is still on track, and I'll diseuss the data presented from the company's recent Investor Day, which may calm some anxious Progyny shareholders I haven't given up on the company yet, but I'm downgrading my rating to ...